KRAS and non-small cell lung carcinoma: KRAS mutations are identified in approximately 90% of pancreatic cancers, 30–40% of colon cancers, and 15–20% of lung cancers, mostly non-small-cell lung cancer (NSCLC) (Pylayeva-Gupta et al., 2011; Singh et al., 2015).